Synthesis and characterisation of antimicrobial metal-organic frameworks as multi-drug carriers

Ahmed Ahmed, Aileen Kelly, Dayle Leonard, Waleed Saleem, Andrey Bezrukov, Constantinos G. Efthymiou, Michael J. Zaworotko, Davide Tiana, Aoife Boyd, Constantina Papatriantafyllopoulou

Research output: Contribution to journalArticlepeer-review

Abstract

Antibiotic resistance is a significant global concern, necessitating the development of either new antibiotics or advanced delivery methods. With this in mind, we report on the synthesis and characterisation of a new family of Metal-Organic Frameworks (MOFs), OnG6 MOFs, designed to act as multi-drug carriers for bacterial infection treatment. OnG6 is based on the pro-drug 4,4′-azodisalicylic acid (AZDH4), which in vivo produces two equivalents of para-aminosalicylic acid (ASA), a crucial drug for M. tuberculosis treatment. X-ray and computational studies revealed that OnG6 MOFs are mesoporous MOFs with etb topology and an [M2(AZD)] formula (M = Zn, OnG6-Zn; Mg, OnG6-Mg; Cu, OnG6-Cu; and Co, OnG6-Co), featuring 1-dimensional channel type pores of 25 Å diameter. OnG6 MOFs are the first reported MOFs bearing the ligand AZDH4, joining the family of mesoporous MOFs arranged in a honeycomb pattern. They absorb isoniazid (INH) and ciprofloxacin (CIPRO) with the former being a specific antibiotic for M. tuberculosis, and the latter being a broader-spectrum antibiotic. The stability of the MOFs and their capacity for antibiotic uptake depend on the nature of the metal ion, with OnG6-Mg demonstrating the highest drug absorption. The antimicrobial activity of these species was assessed against S. aureus and E. coli, revealing that the carriers containing CIPRO displayed optimal efficacy.

Original languageEnglish
Pages (from-to)11867-11875
Number of pages9
JournalDalton Transactions
Volume53
Issue number28
DOIs
Publication statusPublished - 21 Jun 2024

Fingerprint

Dive into the research topics of 'Synthesis and characterisation of antimicrobial metal-organic frameworks as multi-drug carriers'. Together they form a unique fingerprint.

Cite this